Oruka Therapeutics, Inc. (ORKA) NASDAQ
58.53
+0.55(+0.95%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
58.53
+0.55(+0.95%)
Currency In USD
| Previous Close | 57.98 |
| Open | 57.85 |
| Day High | 58.99 |
| Day Low | 56.99 |
| 52-Week High | 91 |
| 52-Week Low | 10.77 |
| Volume | 1.18M |
| Average Volume | 1.45M |
| Market Cap | 2.19B |
| PE | -30.33 |
| EPS | -1.93 |
| Moving Average 50 Days | 60 |
| Moving Average 200 Days | 35.23 |
| Change | 0.55 |
Oruka Therapeutics to Participate in Multiple Upcoming Conferences
GlobeNewswire Inc.
Feb 09, 2026 12:00 PM GMT
MENLO PARK, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases inc
Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001
GlobeNewswire Inc.
Jan 12, 2026 12:00 PM GMT
ORKA-002 interim Phase 1 data demonstrates a half-life of 75-80 days supporting potential for twice-per-year dosing in psoriasis and quarterly dosing in hidradenitis suppurativa Phase 2 studies for ORKA-002 expected to begin in 1H 2026 for psoriasis
Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 06, 2026 12:00 PM GMT
MENLO PARK, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases inc